Related Experiment Videos

Gastrointestinal bleeding in the setting of anticoagulation and antiplatelet therapy

Kassem Barada1, Heitham Abdul-Baki, Ihab I El Hajj

  • 1Department of Internal Medicine, American University of Beirut, Lebanon. kb02@aub.edu.lb

Journal of Clinical Gastroenterology
|July 9, 2008
PubMed

Insights

Patients on antiplatelets or anticoagulants face increased GI bleeding risk. Management involves risk factor assessment, potential anticoagulation reversal, and acid suppression therapy to reduce rebleeding. Further research on a GI bleeding index is recommended.

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Internal Medicine

Background:

  • Antiplatelet and anticoagulant therapies are crucial for preventing thrombotic events.
  • Gastrointestinal (GI) bleeding is a significant complication in patients using these medications.
  • Understanding the nuances of GI bleeding in this population is vital for effective patient management.

Purpose of the Study:

  • To comprehensively review the literature on occult and gross GI bleeding in patients on antiplatelet and/or anticoagulant therapy.
  • To identify risk factors, significance, and management strategies for GI bleeding in this patient group.

Main Methods:

  • Systematic analysis of original and review articles, including bibliographies.
  • Risk and outcome estimates derived from randomized trials.
  • Risk factor identification from cross-control and prospective cohort studies.

Main Results:

  • Antiplatelets/anticoagulants do not impair fecal occult blood testing for GI pathology but increase gross bleeding risk.
  • Key hemorrhage predictors include prior GI bleeding/ulcer, high anticoagulation intensity, combination therapy, and comorbidities.
  • Peptic ulcers are the most common bleeding source; endoscopic hemostasis is feasible with adjusted anticoagulation.
  • Proton-pump inhibitors and H. pylori eradication reduce upper GI bleeding risk in patients with acid-related lesions, even with continued antiplatelet therapy.

Conclusions:

  • Identified bleeding predictors necessitate a validated GI bleeding index for individual risk stratification.
  • Anticoagulation reversal in bleeding patients carries low thromboembolic risk, enabling diagnostic/therapeutic endoscopy.
  • Proton-pump inhibitors and H. pylori eradication are effective in preventing rebleeding from acid-related GI disease.
Abstract

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...